Comparing liver and pancreatic cancers

Surprising similarities in cellular mechanisms drive both liver and pancreatic cancers

PUTNAM VALLEY, NEW YORK, USA, July 2, 2018 / — Putnam Valley, NY (July 2, 2018) – Liver cancer and pancreatic cancer are known to share one statistical outcome – both have poor survival rates. Now, researchers in Belgium have also found that the two deadly cancers share similar tumor developmental mechanisms in terms of tissue types, genetics, and cell mutations, among other similarities. Will this new knowledge lead to better prevention and treatment for both cancers?

The striking similarities between various forms of liver cancer and pancreatic cancer may stem from the liver and the pancreas having developmental similarities in their embryonic stages, said researchers from the Catholic University of Louvain in Brussels, Belgium.

“Because the liver and pancreas are closely associated organs, sharing an embryonic origin, unraveling the process in tumor development in one organ may provide a better understanding of the process in the other organ,” said corresponding author Dr. Patrick Jacquemin.

According to the researchers, the liver and pancreas share molecular properties because they originate in embryonic tissues in adjacent regions, but their advancing development differentiates maturing cells into liver cells (hepatocytes and cholangiocytes) and for the pancreas, endocrine cells (the small “island” cells (the islets of Langerhans) and “exocrine” (acinar) cells, responsible for producing and transporting enzymes.

“Considering their embryonic developmental similarities, we reasoned that some common mechanisms driving tumor development may also be similar,” said co-author Dr. Ivan Borbath of the university’s Department of Hepato-Gastro-Enterology.

In their study, the researchers compared two types of liver cancer (HCC and CCA) to two types of pancreatic cancer (PDAC and ACC). They compared cell type similarities, genetic factors that may cause cell mutations in either organ, and common intracellular “signaling” mechanisms. They also investigated several genetic mutations and pathways and several stood out as significant.

For example, pancreatic ductal adenocarcinoma (PDAC) is one of the most common pancreatic tumors, found in 85 to 95 percent of pancreatic tumors. The authors note that “a striking characteristic of PDAC” is the prevalence of the Kirsten RAt Sarcoma virus (KRAS) mutation found in 88 to 100 percent of PDAC tumors.

KRAS, an “oncogene,” works as an on/off switch and, as a signaling gene, is associated with many cancers when it mutates.

“This very high mutation rate suggests that KRAS plays a key role in pancreatic tumor development,” explained co-author Dr. Elsa Ghurburrun. “The KRAS genetic mutation is also found in CCA liver cancers, but its mutation rate is much less important than in PDAC.”

In both pancreatic cancer and liver cancer, KRAS mutations are also accompanied by two other mutations, GNAS and RNF43.

“The mere presence of KRAS in the acinar genome is not sufficient to initiate tumor development and malignancy,” added co-author Dr. Frederic P. Lemaigre. “Tumor development requires association of a KRAS mutation and inflammation.”

Although the liver and pancreas are closely associated organs sharing an embryonic origin, similar tissue organization, and similar molecular mechanisms that can lead to cancer development, the authors conclude that more knowledge is required to know exactly to what extent pancreatic and liver cancers can be considered similar.

“Current data suggests that mechanisms of tumorigenesis in the liver and pancreas might significantly overlap,” concluded the authors. “However, a more complete understanding of the role of KRAS, GNAS and RNF43 requires the development of new laboratory animal models for testing.”

Their paper appears in the current issue of Gene Expression: The Journal of Liver Research. It is freely available on-line as an unedited, early epub at:


Funding: The study was supported by grants from the Fondation contre le Cancer (Belgium, # 2014-125 to FPL and #2016-089 to PJ) , the Universite catholique de Louvain (# ID 210000.040 to FPL), Televie # 7.4502.16 to FPL and PJ) and the Centre du Cancer (Cliniques universitaires St-Luc). EG holds a Televie fellowship (#7.4600.115). PJ is a Senior Research Associate at the FRS-FNRS (Belgium).


News release by Florida Science Communications

Patrick Jacquemin
Universite catholique de Louvain
+32 2 764 75 31
email us here

Source: EIN Presswire

CONCEPT Professional Training & Palo Alto University Announce Workshop on Workplace Disability Evaluation

Forensic Mental Health workshops

Summer Training at Palo Alto University

CONCEPT Professional Training Workshop on Workplace Disability Evaluation

Summer Training at Palo Alto University

CONCEPT Professional Training and Palo Alto University Announce Summer Training Institute Workshop on Workplace Disability Evaluation

PALO ALTO, CALIFORNIA, UNITED STATES, July 2, 2018 / — CONCEPT Professional Training, a global leader in online professional training in forensic mental health, and Palo Alto University, Northern California's leading school of psychology and counseling, announced today that Dr. Lisa Piechowski will present a 2-day workshop on workplace disability evaluation art this year’s Summer Training Institute at Palo Alto University August 20th – 24th, 2018.

Summer Training Institute is 5 days of mix-and-match professional development workshops presented by internationally renowned experts in forensic psychology.

This year, internationally recognized expert in civil forensic evaluation in a workplace disability context, Dr. Lisa Drago Piechowski, will present a 2-day workshop on Evaluation for Workplace Disability.

This workshop will provide a conceptual framework and practical strategies for forensic evaluations in matters involving disability status such as ADA, disability insurance, and social security. An overview of various types of disability cases will be presented, with an emphasis on the underlying legal context, including recent changes to social security regulations. Next, the basis for the evaluation of disability will be explored focusing on functional assessment. Specific subtopics include avoiding ethical pitfalls, understanding the role of diagnosis, assessing dissimulation, and identifying examiner-related threats to validity. This will be followed by a discussion of practical strategies for designing an effective assessment, organizing and weighing data, and communicating the findings. Participants will have the opportunity to practice these skills through in depth case studies including background information, test data, and collateral information.

This workshop is eligible for continuing education credit. For a complete listing of approvals

For more information on the Summer Training Institute 2018, visit the information page.

Consolidated Continuing Education and Professional Training (CONCEPT) provides expert professional training in areas relevant to criminal and civil forensic mental health assessment, correctional, law enforcement, and forensic intervention. CONCEPT’s professional training programs are presented by the field’s top experts and are based on empirical research and best practices. CONCEPT is dedicated to providing premium professional training, enhanced by technology and e-learning pedagogy, in an accessible online format.

About Palo Alto University (
Palo Alto University (PAU) is a private, nonprofit educational institution, founded in 1975 as the Pacific Graduate School of Psychology (PGSP), an independent, professional school. PGSP was first accredited in 1986 by the regional accrediting body, the Western Association of Schools and Colleges. It has been continuously accredited since then. PGSP re-incorporated as Palo Alto University in August 2009. PAU is dedicated to education with an emphasis in the behavioral and social sciences; to promoting future innovators and leaders for the benefit of society; to generating knowledge through research and scholarship of the highest level; and to providing services to the community informed by science and scholarship.

ConCEPT Professional Training
email us here

Source: EIN Presswire

Clare Ardern Named JOSPT Editor-in-Chief

Clare L. Ardern, PT, PhD, has been appointed editor-in-chief (EIC) of the Journal of Orthopaedic & Sports Physical Therapy® (JOSPT®).

ALEXANDRIA, VIRGINIA, UNITED STATES, July 2, 2018 / — Clare L. Ardern, PT, PhD, has been appointed editor-in-chief (EIC) of the Journal of Orthopaedic & Sports Physical Therapy® (JOSPT®). The first woman to hold this position, Dr Ardern comes to JOSPT having served on the British Journal of Sports Medicine editorial team as deputy editor for systematic reviews.

Beginning July 1, 2018 and for the next year, Dr Ardern will work collaboratively as EIC Elect with Guy G. Simoneau, PT, PhD, ATC, FAPTA, who is currently serving as Interim EIC and previously led JOSPT as EIC for 14 years, from January 2002 through December 2015. Dr Ardern will start work with the JOSPT community by developing new reader- and patient-engagement initiatives for the Journal.

“We look forward to the knowledge, enthusiasm, and energy Dr Ardern brings to JOSPT,” said John A. Nyland, DPT, SCS, EdD, ATC, CSCS, FACSM, president of the JOSPT Board of Directors, which appointed Dr Ardern. “This is, indeed, an exciting time for the Journal, and our organization is fortunate to have such talented editorial leadership.”

“It’s a great honor and a privilege to lead JOSPT,” Dr Ardern said. “I encourage our readers to help shape the Journal and look forward to working together to apply this field’s best research to the care of our patients and athletes.”

Dr Ardern is an Australian physical therapist and sports medicine researcher. Her main research interests are return to sport after injury and how high-caliber meta-research (including systematic reviews, network meta-analyses, and clinical practice guidelines) can help clinicians make quality decisions in practice. For the past decade, her research has focused on understanding how clinicians can best help athletes and active people achieve their sports and physical activity participation goals after injury. Dr Ardern is an expert in outcomes following anterior cruciate ligament injury, with a special focus on how psychological factors influence those outcomes.

She is currently an Australian National Health and Medical Research Council Early Career Fellow in the Division of Physiotherapy at Linköping University in Sweden. In this full-time research position, Dr Ardern leads the development of a mobile application to support recreational athletes in their attempt to safely return to sport after injury. She also serves as a senior collaborator in clinical research on outcomes following treatment for tendinopathy and shoulder, hip, knee, and ankle problems. In addition, Dr Ardern supervises postgraduate research in lower extremity injuries, and is a guest lecturer and tutor in the sports medicine course for the Master of Physiotherapy program at Linköping University.

Since 2011, Dr Ardern has authored nearly 50 peer-reviewed and published articles, which have appeared in many of the leading orthopaedics and sports medicine journals, including JOSPT; British Journal of Sports Medicine; American Journal of Sports Medicine; Arthroscopy; Knee Surgery, Sports Traumatology, Arthroscopy; and Scandinavian Journal of Medicine and Science in Sports. In addition, she has served as a peer reviewer for more than a dozen journals.

Dr Ardern works with a diverse group of orthopaedics and sports researchers in different research settings, across several populations, and in many geographical regions. Her international leadership in sports physical therapy has involved bringing together professionals contributing to the multidisciplinary care of athletes and active people to produce the World Sports Physical Therapy Congress 2016 consensus statement on return to sport and the 2018 International Olympic Committee consensus statement on the prevention, diagnosis, and management of pediatric anterior cruciate ligament injuries. Each project involved more than 20 orthopaedics and sports medicine experts.

Dr Ardern holds both her bachelor's degree in physiotherapy with honors and her doctorate in orthopaedic sports medicine from La Trobe University in Melbourne, Australia. Before coming to Sweden, she worked as a postdoctoral researcher at Aspetar Orthopaedic and Sports Medicine Hospital in Doha, Qatar. She is a member of Sports Medicine Australia and Svensk Förening för Fysisk Aktivitet och Idrottsmedicin (Swedish Association for Physical Activity and Sports Medicine). Formerly an athlete in track and field and soccer, Dr Ardern continues to practice physical activity for a healthy life by biking daily, running, and playing team sports.

For more information, please contact JOSPT Executive Director/Publisher Edith Holmes at, or visit JOSPT is published by JOSPT, Inc. d/b/a Movement Science Media.

Edith Holmes
email us here

Source: EIN Presswire

New Jersey Mesothelioma Victims Center Now Urges a Navy Veteran with Mesothelioma in New Jersey to Call for On the Spot Access to the Nation's Top Attorneys to Achieve the Top Financial Compensation Results

When it comes to mesothelioma compensation for a US Navy Veteran, it is incredibly important the attorney you hire has years of experience with Navy Veteran asbestos exposure cases.”

— New Jersey Mesothelioma Victims Center

NEW YORK, NEW YORK, USA, July 2, 2018 / — The New Jersey Mesothelioma Victims Center is urging a US Navy Veteran who has just been diagnosed with mesothelioma, or their family to please call them anytime at 800-714-0303 so they do not mistakenly hire an inexperienced lawyer/law firm.

The group offers a Navy Veteran with this rare asbestos cancer direct access to some of the nation's most skilled mesothelioma attorneys who exclusively handle mesothelioma compensation claims on a full-time basis. The mesothelioma lawyers the group suggests frequently get million-dollar settlements for Navy Veterans with mesothelioma-especially if the Veteran was exposed to asbestos in a ship's engine room, engineering, or if they served on a nuclear submarine as they would like to discuss at 800-714-0303. http://NewJersey.MesotheliomaVictimsCenter.Com

The New Jersey Mesothelioma Victims Center says, "When it comes to mesothelioma compensation for a US Navy Veteran, it is incredibly important the attorney you hire has years of experience with Navy Veteran asbestos exposure cases. Hiring a local car-accident attorney or personal-injury attorneys to handle a complex mesothelioma compensation claim could result in a navy veteran with mesothelioma getting dramatically shortchanged as we would like to discuss anytime at 800-714-0303. When we mention shortchanged we are referring to hundreds of thousands of dollars-lost.” http://NewJersey.MesotheliomaVictimsCenter.Com

The New Jersey Mesothelioma Victims Center has experience helping US Navy Veterans who were exposed to asbestos on the following types of US Navy ships:

* Destroyers

* Frigates

* Air Craft Carriers

* Battleships (Used during the Vietnam War)

* Cruisers

* Fast Attack Submarines (Los Angeles Class)

* Boomers (Ohio Class Submarine)

* Amphibious Assault Ships

* Troop Transport Ships

* Oilers and Cargo Ships

* Navy Tugs/Support Vessels

For a listing of all former and current US Navy ships, please refer to the US Navy's website that addresses these topics.

The New Jersey Mesothelioma Victims Center wants to emphasize theirs is a statewide initiative available to a diagnosed Veteran or person anywhere in New Jersey, including communities such as Newark, Jersey City, Paterson, Elizabeth, Edison, Toms River, or Trenton. http://NewJersey.MesotheliomaVictimsCenter.Com

For the best possible treatment option in New Jersey, the New Jersey Mesothelioma Victims Center strongly recommends the following heath care facility with the offer to help a diagnosed victim or their family get to the right physicians at this hospital. The Rutgers University’s Cancer Institute of New Jersey in New Brunswick:

According to the CDC, the states indicated with the highest incidence of mesothelioma include Maine, Massachusetts, Connecticut, Maryland, New Jersey, Pennsylvania, Ohio, West Virginia, Virginia, Michigan, Illinois, Minnesota, Louisiana, Washington, and Oregon.

High-risk work groups for exposure to asbestos in New Jersey include US Navy Veterans, power plant workers, oil refinery workers, manufacturing or industrial workers, chemical plant workers, plumbers, electricians, auto mechanics, machinists, mill workers, printers, welders, boiler technicians, or construction workers. Typically, the exposure to asbestos occurred in the 1950’s, 1960’s, 1970’s or 1980’s. http://NewJersey.MesotheliomaVictimsCenter.Com

The Mesothelioma Victims Center is a national advocate 100% focused in on doing everything possible to ensure people with mesothelioma in every state receive the best possible financial compensation settlement. The group offers on the spot access to some of the nation’s most skilled and experienced mesothelioma attorneys because to receive the very best possible financial compensation a diagnosed person must be represented by the most capable mesothelioma lawyers in the United States as they would like to discuss anytime at 800-714-0303. http://MesotheliomaVictimsCenter.Com

For more information about mesothelioma please refer to the National Institutes of Health’s web site related to this rare form of cancer:

Michael Thomas
New Jersey Mesothelioma Victims Center
email us here

Source: EIN Presswire

Chairman Vinod Ramchandra Jadhav and His Team at SAVA Global Announce Latest Generation of Dry Powder Inhalers

SAVA Global is proud to announce the release of their next generation dry powder inhalers.

PUNE, MAHARASHTRA, INDIA, July 2, 2018 / — SAVA Global’s Research and Development Center has been working tirelessly to make the treatment of asthma and asthma-like symptoms easier, more effective, and more efficient. 

SAVA Global understands the importance of dry powder inhalers and has worked hard to make even more improvements on an already great product. SAVA’s Research and Development Center in Pune, India, aided by best-in-class research and development equipment like the Dosage Unit Sampling Apparatus (DUSA), NextGen Impactor (NGI), and Glass Twin Impinger (T1, T2), are ready to announce their new DPI’s: Tiotropium, Formoterol, salmeterol/fluticasone, and Budesonide/Formoterol Fumarate.

Within the global healthcare market, research and development of dry powder inhalers (DPI’s) continue to grow immensely. Many attribute this to their effectiveness, some to their ease of use, but the biggest catalyst for this demand for more and better DPI’s is the increasing incidence of chronic obstructive pulmonary disease (COPD). DPI’s provide a much more efficient delivery system for asthma treatment, an efficiency that is fast becoming a necessity as more people are showing symptoms of COPD across the globe. By easing the delivery of medication through pulmonary routes, COPD sufferers using DPI’s can avoid the potential complications caused by traditional delivery systems.

Under the leadership of Vinod Ramchandra Jadhav, SAVA Global has developed these new dry powder inhalers based on scientific research and data to make them better for everyone who needs them. SAVA’s new DPI’s are easy to use, compact, and efficient. Dry powder inhalers are a great alternative to traditional aerosol-based inhalers (MDI’s) because they deliver medication without requiring the user to coordinate his or her breath with the inhaler. Because they use dry powder, DPI’s can deliver treatment to the lungs more quickly. People suffering from asthma, bronchitis, emphysema, and COPD can receive their treatment quicker, easier, and much more effectively.

With the announcement of these new DPI’s, SAVA Global continues to establish itself as a trailblazer in the healthcare market. SAVA Global is looking toward the future and creating a path to innovation that everyone can follow.

For more information visit:

About Vinod Ramchandra Jadhav: Mr. Jadhav is a first generation entrepreneur with a passion for business. In 2001, he began operating as a franchises owner of a “Medicine Shoppe International” where he learned the ropes of the pharmaceutical industry and got the experience he needed to apply his knowledge of supply chain management on a larger scale. In 2003, he started SAVA Group and has grown the company into an international powerhouse that has footprints in 35 countries around the world. Since then Jadhav has taken his talents to several companies. In addition to being Chairman of SAVA Global, he is Chairman of DEVTECH M2M Group, Director of GangaGen Inc. and Managing Director of Regent Global FZCo.

Vinod Ramchandra Jadhav
SAVA Healthcare Limited
email us here

Source: EIN Presswire